Lates News

Novo Nordisk rose 0.7% in the late session on Wednesday. The company's performance in the third quarter was mixed, with lowered growth expectations. There are also reports that the company has increased its offer for Metsera to a maximum of $10 billion, exceeding Pfizer's $8.1 billion offer. During the antitrust and merger litigation, a judge rejected Pfizer's request to block Novo Nordisk's acquisition attempt.